Cybin is trading 10.1% up today at $10.22 as the stock continues to rally following the appointment of former Intra-Cellular Therapies president Michael Halstead as CEO.
- Michael Halstead is a recognized dealmaker previously linked to a $14.6 billion transaction with Johnson & Johnson, fueling investor optimism regarding the company's strategic direction.
- The stock is benefiting from broader sector strength, with the XBI biotech ETF rising over 2% to provide additional tailwinds.
- This move extends the momentum from August 4, 2026, when shares initially surged 11% following the leadership announcement.